Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Yuyu Pharma Inc. (000220:KRX), powered by AI.
Yuyu Pharma Inc. is currently trading at ₩3,900. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Yuyu Pharma Inc. on Alpha Lenz.
Yuyu Pharma Inc.'s P/E ratio is 8.1.
“Yuyu Pharma Inc. trades at a P/E of 8.1 (undervalued) with modest ROE of 6.4%.”
Ask for details →Yuyu Pharma Inc. is a South Korean pharmaceutical company focused on the research, development, and commercialization of healthcare products. The company's primary function is to provide innovative medical solutions that address unmet needs across various therapeutic areas, including cardiovascular health, oncology, and nervous system disorders. Yuyu Pharma Inc. engages in developing both prescription drugs and over-the-counter medications, offering a diversified product portfolio that contributes to the healthcare sector's evolving landscape. The company's activities have a significant impact on the pharmaceutical supply chain, emphasizing advanced drug delivery systems and sustainable healthcare solutions. In the financial markets, Yuyu Pharma Inc. plays a critical role as a driver of innovation and growth within the biotechnology industry, reflecting the increasing global demand for effective healthcare interventions. Founded with a commitment to improving patient outcomes, Yuyu Pharma Inc. continues to invest in cutting-edge research and strategic collaborations, underscoring its significance and competitive stance in the global pharmaceutical market.
“Yuyu Pharma Inc. trades at a P/E of 8.1 (undervalued) with modest ROE of 6.4%.”
Ask for details →Yuyu Pharma Inc. (ticker: 000220) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 254 employees. Market cap is $66.4B.
The current price is ₩3,900 with a P/E ratio of 8.15x and P/B of 0.51x.
ROE is 6.40% and operating margin is 7.82%. Annual revenue is $140.9B.